Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 1 of 2: Normalized growth rate inhibition values - Dataset (ID:20343)

 Full screen view
Filter results: >>>>
Cell Small Molecule Small Mol Concentration (uM) Primary Target Pathway Mean Normalized Growth Rate Inhibition Value Increased Fraction Dead
BT-549 Etoposide
0.01
Topo II
Chemotherapy
 0.9639 0.01041
BT-549 Etoposide
0.031667
Topo II
Chemotherapy
 0.9288 0.01299
BT-549 Etoposide
0.1
Topo II
Chemotherapy
 0.6702 0.09540
BT-549 Etoposide
0.31623
Topo II
Chemotherapy
 0.3042 0.25698
BT-549 Etoposide
1.0
Topo II
Chemotherapy
 0.0170 0.26509
BT-549 Etoposide
3.1623
Topo II
Chemotherapy
 -0.0386 0.26397
BT-549 Etoposide
10.0
Topo II
Chemotherapy
 -0.1948 0.35550
BT-549 Dasatinib
0.001
BCR/ABL
MAPK/nRTK
 0.9815 0.00139
BT-549 Dasatinib
0.0031623
BCR/ABL
MAPK/nRTK
 1.0599 -0.00162
BT-549 Dasatinib
0.01
BCR/ABL
MAPK/nRTK
 0.9794 0.00180
BT-549 Dasatinib
0.031623
BCR/ABL
MAPK/nRTK
 0.9864 0.01362
BT-549 Dasatinib
0.1
BCR/ABL
MAPK/nRTK
 0.7998 0.02403
BT-549 Dasatinib
0.31623
BCR/ABL
MAPK/nRTK
 0.5622 0.05172
BT-549 Dasatinib
1.0
BCR/ABL
MAPK/nRTK
 0.4889 0.04733
BT-549 Dasatinib
3.1623
BCR/ABL
MAPK/nRTK
 0.5489 0.04455
BT-549 Dasatinib
10.0
BCR/ABL
MAPK/nRTK
 0.3705 0.06119
BT-549 Trametinib
0.0001
MEK
MAPK/nRTK
 1.0281 0.00057
BT-549 Trametinib
0.00031623
MEK
MAPK/nRTK
 1.0022 0.00645
BT-549 Trametinib
0.001
MEK
MAPK/nRTK
 0.9879 0.00807
BT-549 Trametinib
0.0031623
MEK
MAPK/nRTK
 0.9269 0.01053
BT-549 Trametinib
0.01
MEK
MAPK/nRTK
 0.8865 0.01094
BT-549 Trametinib
0.031623
MEK
MAPK/nRTK
 0.8543 0.00533
BT-549 Trametinib
0.1
MEK
MAPK/nRTK
 0.7885 0.02280
BT-549 Trametinib
0.31623
MEK
MAPK/nRTK
 0.7072 0.03421
BT-549 Trametinib
1.0
MEK
MAPK/nRTK
 0.5983 0.03834